FDA Approves Investigational New Drug Application for ALS Cellular Therapy

Press Release:  Novel Cellular Therapeutic Approach for ALS Gets FDA Clearance for First-In-Human Trials

Statement from MDA Scientific Program Officer Amanda Haidet-Phillips, Ph.D.: “This is a promising development in the quest for treatments and cures for ALS. Approval of the Investigational New Drug Application (IND) by the FDA clears the way for a clinical trial of this cellular therapy in ALS patients. We look forward to the outcome of this trial and what we’ll learn from it, and hope it will show encouraging results that bring us one step closer to a cure.”

About MDA

The Muscular Dystrophy Association is the world’s leading nonprofit health agency dedicated to saving and improving the lives of people with muscle disease, including muscular dystrophy, amyotrophic lateral sclerosis (ALS) and other neuromuscular diseases. It does so by funding worldwide research to find treatments and cures; by providing comprehensive health care services and support to MDA families nationwide; and by rallying communities to fight back through advocacy, fundraising and local engagement.

Visit mda.org and follow us at facebook.com/MDAnational and @MDAnews. Learn more about MDA’s mission by watching this video.

Claire Orphan
Media Relations Manager
corphan@mdausa.org